RECURRENT PROSTATE CARCINOMA

This phase II trial tests two types of radiation therapy (proton beam or IMRT) given in fewer, larger doses for men whose prostate cancer has returned or spread to a few spots after initial treatment. The main goal is to see if this shorter course causes fewer serious side effect…

This phase 2 trial tests whether white button mushroom extract can lower PSA levels in men with prostate cancer that has returned after treatment or is low-risk and not yet treated. About 133 men will take the supplement or be observed. The goal is to see if the mushroom affects …

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This study tests whether adding the immunotherapy drug pembrolizumab can help men whose advanced prostate cancer has stopped responding to the standard drug enzalutamide. About 58 men with castration-resistant prostate cancer that has spread will receive pembrolizumab while conti…

This study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in people with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can lowe…

This study tests whether adding abiraterone and prednisone to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has come back after surgery or radiation. About 310 men will receive either hormone therapy or hormone therapy plus abirate…

This phase II trial is testing whether combining antiandrogen drugs (leuprolide, apalutamide, abiraterone) with precise radiation (SBRT) can control prostate cancer that has come back and spread to a few other spots in the body. The study enrolls 28 men whose cancer has 1-5 visib…

This phase 2 trial is testing whether surgery and radiation can help men whose prostate cancer has come back and spread to a few spots in the body. About 20 participants will receive either surgery to remove the spread tumors or targeted radiation, or both. The main goal is to se…

This study is for men whose prostate cancer has returned after prostate removal surgery, shown by a rising PSA. It compares standard radiation therapy alone versus radiation plus a drug called apalutamide, which blocks male hormones that fuel cancer growth. The goal is to see if …

This study tests whether a special PET/CT scan (68Ga-PSMA-11) can help doctors plan more precise radiation for men whose prostate cancer has come back after surgery. About 193 men with a rising PSA level will be randomly assigned to have their radiation plan based on either the n…

This study tests whether adding furosemide, a diuretic that increases urine flow, to a special PET/CT scan can reduce bladder radioactivity and improve detection of recurrent prostate cancer in 20 men whose PSA levels have risen after prostate removal. The goal is to see if this …

This phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at how certain hormone therapies for advanced prostate cancer might affect memory, thinking, and brain structure. Researchers will use brain scans and thinking tests in 100 men to track changes over time. The goal is to understand which patients are more likely t…

This study looks at genes in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. Researchers will analyze tissue, blood, and urine samples from 92 patients receiving a drug called abiraterone. The goal is to find genetic changes that …